ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

VRAX Virax Biolabs Group Ltd

1,721
0,001 (0,06%)
19 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Virax Biolabs Group Ltd VRAX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,001 0,06% 1,721 01:54:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,71 1,65 1,77 1,72 1,72
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/6/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/4/202414:00PRNUSVirax Biolabs Launches Portfolio of Immune Profiling..
16/4/202413:30PRNUSVirax Biolabs to Participate at ESCMID Global 2024
15/3/202421:30PRNUSVirax Biolabs Announces Receipt of NASDAQ Notification..
22/1/202423:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/1/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/1/202413:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202313:30PRNUSVirax Biolabs Forges Strategic Research Collaboration with..
20/12/202322:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/12/202322:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202322:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/12/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/12/202313:30PRNUSVirax Biolabs' CEO James Foster Issues Letter to..
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14/12/202313:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202313:30PRNUSVirax Biolabs Group Limited Announces 1-for-10 Share..
08/12/202312:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
08/11/202322:11EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202321:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202313:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:30PRNUSVirax Biolabs Group Announces Early-Access Program Launch of..
01/9/202313:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/9/202313:30PRNUSVirax Biolabs Group Appoints Dr. Nigel McCracken as Chief..
03/8/202314:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202313:30PRNUSNasdaq Approves 180-Day Extension for Virax Biolabs Group to..
18/7/202313:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202313:30PRNUSVirax Biolabs Group Continues Growth and Expansion with the..